You signed in with another tab or window. Reload to refresh your session.You signed out in another tab or window. Reload to refresh your session.You switched accounts on another tab or window. Reload to refresh your session.Dismiss alert
Personalized alloreactive cellular immunotherapy platform based on Activated Targeted Alloreactive Killer cells (ATACK), developed from earlier IMAK concepts and enhanced with monoclonal antibody targeting of overexpressed tumor antigens.